share_log

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright&Co.以买入评级启动对Akari治疗公司的报道,宣布目标价为1.5美元
Benzinga Real-time News ·  2022/12/05 06:10

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.

HC Wainwright&Co.分析师肖恩·李以买入评级启动对阿卡里治疗公司(纳斯达克:AKTX)的报道,并宣布目标价为1.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发